A new study shows there may be a new way to help psoriasis patients.
A key protein called TWEAK that damages skin cells in psoriasis patients is demonstrated by researchers at Lji's center for autoimmunity and Inflammation. These findings are published in the journal Science Immunology. About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes.
Although there are effective treatments for psoriasis, not everyone responds to these therapies and the relief is temporary.
"These therapies don't reduce disease by 100 percent, and they don't cure the disease, and if you take patients off those drugs, the disease almost always comes back”, says La Jolla Institute for Immunology (LJI) Professor Michael Croft, Ph.D.
Researchers thought that TWEAK protein might be a potential target for psoriasis to develop a new therapeutic option.
Based on the previous findings that TWEAK can interact with the most common type of skin, researchers investigated TWEAK-deficient mice and found that TWEAK is a driver of inflammation in psoriasis.
The new study also shows that TWEAK does not work alone, it teams up with two other proteins, called tumor necrosis factor (TNF) and interleukin-17 (IL-17), to trigger inflammation. This trio appears to control psoriasis.
Advertisement
To test this, the researchers used a mouse model of psoriasis to compare how well a TWEAK-inhibitor measured up to therapies inhibiting IL-17 or TNF.
Advertisement
Although human clinical trials remain to be done, a future for TWEAK inhibitors as therapies for many types of skin diseases is bright.
Source-Medindia